Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 306

1.

Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation.

Kamel H, Easton JD, Johnston SC, Kim AS.

Neurology. 2012 Oct 2;79(14):1428-34. doi: 10.1212/WNL.0b013e31826d5fe8. Epub 2012 Sep 19.

2.

Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation.

Lee S, Mullin R, Blazawski J, Coleman CI.

PLoS One. 2012;7(10):e47473. doi: 10.1371/journal.pone.0047473. Epub 2012 Oct 9.

3.

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.

Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC.

Stroke. 2013 Jun;44(6):1676-81. doi: 10.1161/STROKEAHA.111.000402. Epub 2013 Apr 2.

4.

Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.

Dorian P, Kongnakorn T, Phatak H, Rublee DA, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Lip GY.

Eur Heart J. 2014 Jul 21;35(28):1897-906. doi: 10.1093/eurheartj/ehu006. Epub 2014 Feb 9.

5.

Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.

Lee S, Anglade MW, Meng J, Hagstrom K, Kluger J, Coleman CI.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):472-9. doi: 10.1161/CIRCOUTCOMES.112.965251. Epub 2012 Jun 26.

6.

Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.

Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, Wells GA.

Value Health. 2013 Jun;16(4):498-506. doi: 10.1016/j.jval.2013.01.009. Epub 2013 Apr 23.

7.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.

Kamel H, Johnston SC, Easton JD, Kim AS.

Stroke. 2012 Mar;43(3):881-3. doi: 10.1161/STROKEAHA.111.641027. Epub 2012 Feb 3.

8.

Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.

Lanitis T, Kongnakorn T, Jacobson L, De Geer A.

Thromb Res. 2014 Aug;134(2):278-87. doi: 10.1016/j.thromres.2014.05.027. Epub 2014 May 26.

9.

Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.

Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P.

Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011. Epub 2014 Feb 6.

10.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
11.

Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.

Ademi Z, Pasupathi K, Liew D.

Eur J Prev Cardiol. 2015 Mar;22(3):344-53. doi: 10.1177/2047487313514019. Epub 2013 Nov 26.

PMID:
24281250
12.
13.

Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan.

Kamae I, Hashimoto Y, Koretsune Y, Tanahashi N, Murata T, Phatak H, Liu LZ, Tang AC, Feng Wang P, Okumura K.

Clin Ther. 2015 Dec 1;37(12):2837-51. doi: 10.1016/j.clinthera.2015.10.007. Epub 2015 Nov 19.

14.

Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.

Lanitis T, Cotté FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I.

J Med Econ. 2014 Aug;17(8):587-98. doi: 10.3111/13696998.2014.923891. Epub 2014 May 29.

PMID:
24831811
15.

Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.

Wisløff T, Hagen G, Klemp M.

Pharmacoeconomics. 2014 Jun;32(6):601-12. doi: 10.1007/s40273-014-0152-z.

16.

Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation.

Amin A, Stokes M, Wu N, Gatt E, Makenbaeva D, Wiederkehr D, Boulanger L.

J Med Econ. 2013 Oct;16(10):1193-202. doi: 10.3111/13696998.2013.828064. Epub 2013 Aug 7.

PMID:
23883416
17.

Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.

Athanasakis K, Karampli E, Tsounis D, Bilitou A, Kyriopoulos J.

Clin Drug Investig. 2015 Nov;35(11):693-705. doi: 10.1007/s40261-015-0321-7.

PMID:
26385756
18.

Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation.

Canestaro WJ, Patrick AR, Avorn J, Ito K, Matlin OS, Brennan TA, Shrank WH, Choudhry NK.

Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):724-31. doi: 10.1161/CIRCOUTCOMES.113.000661. Epub 2013 Nov 12.

19.

Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.

Zheng Y, Sorensen SV, Gonschior AK, Noack H, Heinrich-Nols J, Sunderland T, Kansal AR.

Clin Ther. 2014 Dec 1;36(12):2015-2028.e2. doi: 10.1016/j.clinthera.2014.09.015. Epub 2014 Oct 23.

20.

Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.

Rognoni C, Marchetti M, Quaglini S, Liberato NL.

Clin Drug Investig. 2014 Jan;34(1):9-17. doi: 10.1007/s40261-013-0144-3.

PMID:
24135964
Items per page

Supplemental Content

Write to the Help Desk